In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.